Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Research & Development: 2009-2024

Historic Research & Development for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to $74.4 million.

  • Vanda Pharmaceuticals' Research & Development rose 34.50% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.1 million, marking a year-over-year increase of 26.83%. This contributed to the annual value of $74.4 million for FY2024, which is 3.11% down from last year.
  • Vanda Pharmaceuticals' Research & Development amounted to $74.4 million in FY2024, which was down 3.11% from $76.8 million recorded in FY2023.
  • Vanda Pharmaceuticals' 5-year Research & Development high stood at $85.8 million for FY2022, and its period low was $55.6 million during FY2020.
  • Its 3-year average for Research & Development is $79.0 million, with a median of $76.8 million in 2023.
  • In the last 5 years, Vanda Pharmaceuticals' Research & Development soared by 35.60% in 2021 and then dropped by 10.43% in 2023.
  • Over the past 5 years, Vanda Pharmaceuticals' Research & Development (Yearly) stood at $55.6 million in 2020, then skyrocketed by 35.60% to $75.4 million in 2021, then grew by 13.81% to $85.8 million in 2022, then fell by 10.43% to $76.8 million in 2023, then fell by 3.11% to $74.4 million in 2024.